Annexin-I overexpression is associated with tumour progression and independently predicts inferior disease-specific and metastasis-free survival in urinary bladder urothelial carcinoma

Pathology

Volumn 42, Issue 1, 2010, Pages 43-49

  Li, Chien Feng ^a,b   Shen, Kun Hung ^a,c,d   Huang, Li Chien ^e   Huang, Hsuan Ying ^f   Wang, Yu Hui ^a   Wu, Ting Feng ^e  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^e SOUTHERN TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^f CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Prognosis

Indexed keywords

EID: 73649102769     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.3109/00313020903434405     Document Type: Article

References (35)

1. Bane BL, Rao JY, Hemstreet GP. Pathology and staging of bladder cancer. Semin Oncol 1996; 23: 546-570
2. Stein JP, Grossfeld GD, Ginsberg DA, et al. Prognostic markers in bladder cancer: A contemporary review of the literature. J Urol 1998; 160: 645-659
3. Zieger K, Wolf H, Olsen PR, Hojgaard K. Long-term follow-up of noninvasive bladder tumours (stage Ta): Recurrence and progression. BJU Int 2000; 85: 824-828
4. Dey P. Urinary markers of bladder carcinoma. Clin Chim Acta 2004; 340: 57-65.
5. Bassi P, De Marco V, De Lisa A, et al. Non-invasive diagnostic tests for bladder cancer: A review of the literature. Urol Int 2005; 75: 193-200.
6. Lim LH, Pervaiz S. Annexin 1: The new face of an old molecule. FASEB J 2007; 21: 968-975
7. Croxtall JD, Choudhury Q, Tokumoto H, Flower RJ. Lipocortin-1 and the control of arachidonic acid release in cell signalling. Glucocorticoids (changed from glucorticoids) inhibit G proteindependent activation of cPLA2 activity. Biochem Pharmacol 1995; 50: 465-474
8. Paul-Clark MJ, Gavins FN, Perretti M, Morris JF, Buckingham JC, Flower RJ. Aberrant inflammation and resistance to glucocorticoids in annexin 17/7 mouse. FASEB J 2003; 17: 253-255
9. Ferreira SH, Cunha FQ, Lorenzetti BB, et al. Role of lipocortin-1 in the anti-hyperalgesic actions of dexamethasone. Br J Pharmacol 1997; 12: 1883-1888
10. Marie F, Solito E. Annexin 1 expression and phosphorylation are upregulated during liver regeneration and transformation in antithrombin III SV40 T large antigen transgenic mice. Hepatology 2000; 31: 371-380
11. Skouteris GG, Schroder CH. The hepatocyte growth factor receptor kinase-mediated phosphorylation of lipocortin-1 transduces the proliferating signal of the hepatocyte growth factor. J Biol Chem 1996; 271: 27266-27273
12. Croxtall J, Flower R, Perretti M. The role of lipocortin 1 in the regulation of A549 cell proliferation and leukocyte migration. J Lipid Mediat 1993; 6: 295-302.
13. Croxtall JD, Waheed S, Choudhury Q, Anand R, Flower RJ. Nterminal peptide fragments of lipocortin-1 inhibit A549 cell growth and block EGF-induced stimulation of proliferation. Int J Cancer 1993; 54: 153-158
14. Alldridge LC, Harris HJ, Plevin R, Hannon R, Bryant CE. The annexin protein lipocortin 1 regulates the MAPK/ERK pathway. J Biol Chem 1999; 274: 37620-37628
15. Dorovkov MV, Ryazanov AG. Phosphorylation of annexin I by TRPM7 channel-kinase. J Biol Chem 2004; 279: 50643-50646
16. Varticovski L, Chahwala SB, Whitman M, et al. Location of sites in human lipocortin I that are phosphorylated by protein tyrosine kinases and protein kinases A and C. Biochemistry 1988; 27: 3682-3690
17. Kang JS, Calvo BF, Maygarden SJ, Caskey LS, Mohler JL, Ornstein DK. Dysregulation of annexin I protein expression in high-grade prostatic intraepithelial neoplasia and prostate cancer. Clin Cancer Res 2002; 8: 117-123
18. Ahn SH, Sawada H, Ro JY, Nicolson GL. Differential expression of annexin I in human mammary ductal epithelial cells in normal and benign and malignant breast tissues. Clin Exp Metastasis 1997; 15: 151-156
19. Masaki T, Tokuda M, Ohnishi M, et al. Enhanced expression of the protein kinase substrate annexin in human hepatocellular carcinoma. Hepatology 1996; 24: 72-81.
20. Bai XF, Ni XG, Zhao P, et al. Overexpression of annexin 1 in pancreatic cancer and its clinical significance. World J Gastroenterol 2004; 10: 1466-1470
21. Hu N, Flaig MJ, Su H, et al. Comprehensive characterization of annexin I alterations in esophageal squamous cell carcinoma. Clin Cancer Res 2004; 10: 6013-6022 (Pubitemid 39302608)
22. Johnson MD, Kamso-Pratt J, Pepinsky RB, Whetsell WO Jr. Lipocortin-1 immunoreactivity in central and peripheral nervous system glial tumors. Hum Pathol 1989; 20: 772-776 (Pubitemid 19203639)
23. Hippo Y, Yashiro M, Ishii M, et al. Differential gene expression profiles of scirrhous gastric cancer cells with high metastatic potential to peritoneum or lymph nodes. Cancer Res 2001; 61: 889-895
24. Rodrigo JP, Garcia-Pedrero JM, Fernandez MP, Morgan RO, Suá rez C, Herrero A. Annexin A1 expression in nasopharyngeal carcinoma correlates with squamous differentiation. Am J Rhinol 2005; 19: 483-487
25. Silistino-Souza R, Rodrigues-Lisoni FC, Cury PM, et al. Annexin 1: Differential expression in tumor and mast cells in human larynx cancer. Int J Cancer 2007; 120: 2582-2589
26. Garcia Pedrero JM, Fernandez MP, Morgan RO, et al. Annexin A1 down-regulation in head and neck cancer is associated with epithelial differentiation status. Am J Pathol 2004; 164: 73-79
27. Sheng KH, Yao YC, Chuang SS, Wu H, Wu TF. Search for the tumorrelated proteins of transition cell carcinoma in Taiwan by proteomic analysis. Proteomics 2006; 6: 1058-1065
28. Xiao GS, Jin YS, Lu QY, et al. Annexin-I as a potential target for green tea extract induced actin remodeling. Int J Cancer 2007; 120: 111-120
29. Hayes MJ, Rescher U, Gerke V, Moss SE. Annexin-actin interactions. Traffic 2004; 5: 571-576
30. Alvarez-Martinez MT, Mani JC, Porte F, Faivre-Sarrailh C, Liautard JP, Sri Widada J. Characterization of the interaction between annexin I and profilin. Eur J Biochem 1996; 238: 777-784
31. Rao J. Targeting actin remodeling profiles for the detection and management of urothelial cancers-a perspective for bladder cancer research. Front Biosci 2002; 7: E1-8.
32. Savagner P. Leaving the neighborhood: Molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays 2001; 23: 912-923
33. Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology 2007; 39: 305-318
34. Wu YL, Jiang XR, Lillington DM, Newland AC, Kelsey SM. Upregulation of lipocortin 1 inhibits tumour necrosis factor-induced apoptosis in human leukaemic cells: A possible mechanism of resistance to immune surveillance. Br J Haematol 2000; 111: 807-816
35. Carollo M, Parente L, D'Alessandro N. Dexamethasone-induced cytotoxic activity and drug resistance effects in androgen-independent prostate tumor PC-3 cells are mediated by lipocortin 1. Oncol Res 1998; 10: 245-254